Interim report
Page 1
STARSOURCE MULTITRADE LIMITED (Formerly known as Chemo Pharm Laboratories Limited) (CIN: L46900MH1942PLC003556) Registered Office : 5-Kumud Apartment Co. Op. HSG. SOC. Ltd, Karnik Road, Chikan Ghar, Kalyan, Dist. Thane – 421301 Corporate Office: Office No 1016, North Plaza, Near D Mart, Visat Gandhinagar Highway, Motera, Ahmedabad, Gujarat, India – 380005 Tel. No.:022-22078382 Website: www.thechemopharmalaboratoriesltd.com Email : chemopharmalaboratorieslimited@gmail.com Date: February 12, 2026 To, Bombay Stock Exchange Limited Department of Corporate Services, 25th Floor, P. J. Towers, Dalal Street, Mumbai-400001 Script Id: 506365 ISIN: INE320M01019 Subject: Outcome of Board Meeting held on Thursday, February 12, 2026. Dear Sir / Madam, Pursuant to Regulation 33 of the Securities and Exc hange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Thursday, February 12, 2026 at the Registered Office of the Company, inter alia, have considered and approved the following: 1. Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2025. 2. Limited Review Report on the Un-audited Financial R esults of the Company for the quarter ended on December 31, 2025. The Un-audited Financial Results (Standalone and Co nsolidated) for the quarter ended December 31, 2025 along with the limited review reports thereon are enclosed herewith. The aforesaid information is also available on website of the company. The meeting commenced at 12:00 PM and concluded at 12:45 PM. The same may please be taken on record. Thanking You. Yours Faithfully, FOR STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITE D) RUCHIT MEHTA Managing Director & Chief Executive Officer DIN: 08810586
Page 3
Year ended 31st Dec 2025 30th Sep 2025 31st Dec 2024 31st Dec 2025 31st Dec 2024 31st March 2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Revenue from operations 0.00 5256.56 0.00 5256.56 0.00 0.00 II Other income 0.00 0.00 (1488.00) 207.12 7839.00 6198.00 III TOTAL REVENUE 0.00 5256.56 (1488.00) 5463.68 7839.00 6198.00 IV EXPENSES (1) Cost of materials consumed 0.00 0.00 0.00 0.00 0.00 0.00 (2) Purchases of stock-in-trade 0.00 3765.35 0.00 3765.35 0.00 0.00 (3) Changes in inventories of finished goods, work-in- progress and stock-in-trade 0.00 0.00 0.00 0.00 0.00 0.00 (4) Employee benefits expense 216.00 216.00 54.00 672.60 177.00 216.00 (5) Finance costs 0.00 0.59 0.00 5.97 0.00 0.00 (6) Depreciation and amortisation expense 0.00 0.00 14.00 0.00 41.00 54.00 (7) Administrative & Other expenses 649.11 294.48 192.00 118955.38 803.00 947.00 TOTAL EXPENSES 865.11 4276.42 260.00 123399.30 1021.00 1217.00 V Profit/(Loss) before exceptional items & tax (865.11) 980.14 (1748.00) (117935.62) 6818.00 4981.00 VI Exceptional items (net charge) 0.00 0.00 0.00 0.00 0.00 0.00 VII Net Profit before ExtraOrdinaray Items & Tax (865.11) 980.14 (1748.00) (117935.62) 6818.00 4981.00 VIII Extraordinary Items 0.00 0.00 0.00 0.00 0.00 0.00 IX Profit before Tax (865.11) 980.14 (1748.00) (117935.62) 6818.00 4981.00 X Tax Expenses (1) Current tax 0.00 0.00 0.00 0.00 0.00 1993.00 (2) Tax Aduustment Previous Year 0.00 0.00 0.00 0.00 0.00 0.00 (3) Deferred tax credit/(charge) 0.00 0.00 0.00 0.00 0.00 (435.00) (4) MAT Credit Entitlement 0.00 0.00 0.00 0.00 0.00 0.00 XI PROFIT/Loss FOR THE PERIOD from continious operations (865.11) 980.14 (1748.00) (117935.62) 6818.00 3423.00 XII PROFIT/Loss from dis-continious operations 0.00 0.00 0.00 0.00 0.00 0.00 XIII Tax expenses for dis-continious operations 0.00 0.00 0.00 0.00 0.00 0.00 XIV PROFIT/Loss FOR THE PERIOD from dis-continious operations 0.00 0.00 0.00 0.00 0.00 0.00 XV PROFIT/Loss FOR THE PERIOD (865.11) 980.14 (1748.00) (117935.62) 6818.00 3423.00 XVI OTHER COMPREHENSIVE INCOME A(i)Items that will not be reclassified subsequently to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 (ii) Income Tax relating to Items that will not be reclassified subsequently to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 XVII TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (Comprising Profit/(Loss) and other comprehensive income for the period (865.11) 980.14 (1748.00) (117935.62) 6818.00 3423.00 XVIIIEarnings per equity share (1) Basic -0.58 0.65 -1.17 -78.62 4.55 2.28 (2) Diluted -0.58 0.65 -1.17 -78.62 4.55 2.28 Date: 12.02.2026 Place: Mumbai ParticularsSr. No (Rupees in Thoudsand) STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED) STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025 DIN: 08810586 RUCHIT MEHTA MD & CEO Quarter ended Nine Months Ended FOR STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)
Page 4
Date: 12.02.2026 Place: Mumbai RUCHIT MEHTA MD & CEO DIN: 08810586 Notes: 1. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies . (Indian Accounting Standard) Accounting Rules, 2016. 2. The above Standalone Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2025 have been reviewed by the Audit Committee in their Mecting held on 12.02.2026 and approved by the Board of Directors of its Meeting held on 12.02.2026. The Limited Review Report of Auditors M/s S S R V & Associates was also taken on record by the Board in its Meeting. 3 The Company is not having any Subsidary Company. 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in ‘Operating Segment'. FOR STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)
Page 5
AUDITED YEAR ENDED 31.12.2025 30.09.2025 31.12.2024 31.12.2025 31.12.2024 31.03.2025 Reconciliation of Profit After Tax as reported earlier: Net Profit / (Loss) for the Period (as per AS) -865.11 980.14 1,210.00 -1,18,142.14 4,533.00 -1,837.00 Benefit / (Charge): Impact of Deferred Income (Government Grant) Amortized to Income 0.00 0.00 0.00 0.00 0.00 0.00 Impact of Fair Valuation of Financial Instruments 0.00 0.00 -2,958.00 1,16,595.65 2,285.00 1,993.00 Impact of Actuarial Gain / Loss Taken OCI 0.00 0.00 0.00 0.00 0.00 0.00 Impact of Adjustment of Deferred Tax 0.00 0.00 0.00 0.00 0.00 -435.00 Impact of Adjustment of MAT Credit Entitlement 0.00 0.00 0.00 0.00 0.00 0.00 Net Profit / (Loss) for the Period (as per AS) -865.11 980.14 -1,748.00 -1,546.49 6,818.00 -3,396.00 RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025 (Rs. In Thousands) PARTICULARS UNAUDITED QUARTER ENDED STANDALONE UNAUDITED NINE MONTHS ENDED
Page 6
Sr. No Particulars Remarks 1 B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. NOT APPLICABLE 2 C. Format for disclosing outstanding default on loans and debt securities NOT APPLICABLE 3 D. Format for disclosure of related party transactions (applicable only for half yearly filings i.e. , 2nd and 4th quarter) NOT APPLICABLE 4 E. Statement on impact of audit qualifications (for audit report with modified opinion ) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter) NOT APPLICABLE Date: 12.02.2026 RUCHIT MEHTA Place: Mumbai MD & CEO DIN: 08810586 OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) - FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2025 (In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated December 31, 2024) FOR STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)